Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Neuronetics (STIM) Long-Term Debt Repayments (2020 - 2026)

Neuronetics (STIM) reported Long-Term Debt Repayments of $5.0 million for Q1 2026, up 316.67% on a QoQ basis from $1.2 million in Q1 2023.

Neuronetics (STIM) has 3 years of Long-Term Debt Repayments data on file, last reported at $5.0 million in Q1 2026.

  • Quarterly Long-Term Debt Repayments changed N/A year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (changed N/A YoY) and the FY2025 annual result came in at $211000.0, down 99.65% from the prior year.
  • Long-Term Debt Repayments advanced to $5.0 million in Q1 2026 per STIM's latest filing, from $1.2 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $5.0 million in Q1 2026 and bottomed at $1.2 million in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Neuronetics 3.26 Mn -6.42 Mn 16.15 Mn 5.00 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 5.00 Mn
Mar 31, 2026 5.00 Mn
Mar 31, 2023 1.20 Mn
Mar 31, 2023 1.20 Mn
Jun 30, 2020 6.36 Mn
Jun 30, 2020 6.36 Mn
Mar 31, 2020 32.50 Mn
Mar 31, 2020 32.50 Mn